Evaluation of Long Term Safety of Tesofensine in Patients With Obesity

Inclusion Criteria: Patients who have completed their participation in TIPO-1 * Males and females 18 to 65,5 years of age, extremes included * Patients continuously receiving diet therapy as well as instructions on exercise * Females of childbearing potential must be non-pregnant and use safe contraceptive methods (the pill, IUD, injection of prolonged gestagen, sub dermal implantation, hormonal vaginal devices, transdermal patches or surgically sterilized) * Patients should be able to comply with study procedures * Patients giving written informed consent Exclusion Criteria: * Patients with a BMI\< 22 * Use of prescription medication as listed in Appendix 1 * Positive pregnancy test for women of childbearing potential * Pregnant women, or women who are planning to become pregnant within the next 8 months * Patients with specific diseases interfering with their metabolism e.g. untreated myxoedema, Cushing's syndrome, Type 1 diabetes mellitus, significant neurological or psychiatric illness such as epilepsy, schizophrenia, depression, eating disorders such as bulimia. * Patients with Type 2 diabetes mellitus are ineligible unless anti-diabetic medication was not deemed necessary by the investigator and fasting (venous or arterialized capillary full blood from finger or ear) blood glucose \> 6.1 mmol/l at screening. Re-test is allowed if first measure is above inclusion value. The corresponding exclusion criteria for plasma glucose is 7.0 mmol/l * Patients known to abuse or to be dependent on any drug, including alcohol (weekly consumption \> 21 units of alcohol (men) or \>14 units of alcohol (women)) * Hepatic or renal dysfunction (ASAT and/or ALAT \> 2 x ULN and creatinine clearance \< 30 mL/min estimated by central laboratory using Cockcroft and Gault formula, respectively) * Known untreated hypercholesterolaemia (\> 7 mmol/l). Patients with well regulated cholesterol using drugs for hypercholesterolaemia are allowed inclusion * Known untreated hypertriglyceridaemia (\> 3 mmol/l). Patients with well regulated triglyceride levels using drugs for hypertriglyceridaemia are allowed inclusion * Drug treated thyroid diseases (well substituted hypothyroidism is allowed) * Patients who suffer from hyperthyroid disease are not allowed in the study, even though they may be well treated by drugs * Patients, who have recently diagnosed, not yet stable hypothyroid disease are not allowed in the study * Patients who suffer from longstanding stable hypothyroid disease, well treated substitution are allowed to be included including hypothyroidism as a sequelae to definitive treatment of hyperthyroidism by surgery or radioactive iodine * Malabsorptive intestinal disorders that can be assumed to affect the absorption of tesofensine * Special diets (e.g., vegetarian, Atkins) * Patients planning major changes in physical activity during the study to an extent that may interfere with the study outcome, as judged by the investigator * Mental or psychiatric disorder based on medical history only * Surgically treated obesity * Patients with systemic infections or inflammatory diseases * History or presence of significant cardiovascular disease such as heart failure, ischemic heart disease, stroke, transient ischemic attacks * Significant abnormalities on the ECG. according to the investigators opinion. Additional exclusionary ECG values: QTcB \> 480 milliseconds (ms) in females and \>450 ms in males, PR interval \> 240 ms, QRS interval \> 120 ms * Hypotension (i.e. supine systolic BP \< 90 mm Hg) and/or symptomatic orthostatic hypotension (clinical symptoms of orthostatic hypotension associated with a decline ≥ 20 mm Hg in systolic BP at one minute after standing compared with the previous supine systolic BP obtained after 5 minutes of quiet rest) at screening visit * Uncontrolled hypertension (i.e. sitting diastolic BP ≥ 95 mm Hg and sitting systolic BP ≥ 155 mm Hg) despite treatment for \> 4 weeks prior to the screening visit as well as HR\>90 bpm * Known HIV infection (no tests required) * History of cancer within the past 5 years, excluding treated basal cell carcinoma * Clinically significant or potentially disabling eye disorder, including uncontrolled glaucoma * Current treatment with medication with known ocular toxicity such as chloroquine and hydroxychloroquine is prohibited * Patients treated with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study drug